Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: The NOGOMA study [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 4, 2007, Pages 477-479

  Canestri, Ana ^a   Cisse, Mamadou ^b   Marcelin, Anne Geneviève ^a   Peytavin, Gilles ^c   Traore, Emmanuel ^b   Assoumou, Lambert ^a   Traore, Ousmane ^b   Koita, Victoria ^b   Diallo, Fodie ^b   Sangare, Awa Thiero ^d   Sidibé, Mayrama Koita ^e   Calvez, Vincent ^a   Sylla, Aliou ^b   Katlama, Christine ^a   Tubiana, Roland ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Centre de Soins d'Animation et de Conseil Pour Les Personnes Vivant Avec Le VIH/SIDA   (Mali)

^c BICHAT HOSPITAL   (France)

^d Institut National de Recherche en Sante Publique Mali   (Mali)

^e Hopital National du Point G   (Mali)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; RITONAVIR; VIRUS RNA;

ADULT; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; MALE; MALI; NEPHROLITHIASIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MALI; MIDDLE AGED; PILOT PROJECTS; RITONAVIR; TREATMENT OUTCOME;

EID: 34447300742     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318061b5c3     Document Type: Letter

References (17)

1. World Health Organization. WHO launches guidelines to speed up delivery of antiretroviral drugs to HIV/AIDS patients. Bull World Health Organ. 2003;81:852-853.
2. Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther. 2004;9:3-12.
3. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005;40:336-343.
4. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing anti-retroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895.
5. Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2001;26:501-506.
6. Ghosn J, Lamotte C, Ait-Mohand H, et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS. 2003;17:209-214.
7. Duvivier C, Myrto A, Marcelin AG, et al. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antivir Ther. 2003;8:603-609.
8. Boyd M, Mootsikapun P, Burger D, et al. Pharmacokinetics of reduced-dose indinavir/-ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther. 2005;10:301-307.
9. Konopnicki D, De Wit S, Poll B, et al. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily. HIV Med. 2005;6:1-6.
10. 3: 96-week outcomes. Antivir Ther. 2005;10:911-916.
11. Justesen US, Levring AM, Thomsen A, et al. Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome followup. HIV Med. 2003;4:250-254.
12. Wasmuth JC, la Porte CJ, Schneider K, et al. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). Antivir Ther. 2004;9:213-220.
13. Cressey TR, Leenasirimakul P, Jourdain G, et al. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J Antimicrob Chemother. 2005;55:1041-1044.
14. Woolf E, Au T, Haddix H, et al. Determination of L-735 524, a human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr A. 1995;692:45-52.
15. Lamotte C, Peytavin G, Chavanet P, et al. Increasing adverse events with indinavir dosages and plasma concentrations in four different ritonavir-indinavir containing regimens in HIV-infected patients. Presented at: Eighth Conference on Retroviruses and Opportunistic Infections; 2001; Chicago.
16. Burger D, Boyd M, Duncombe C, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother. 2003;51:1231-1238.
17. Tubiana RDS, Perot C, Cornelie C, et al. ART with indinavir-ritonavir (400 mg/100 mg twice daily)-containing regimen in HIV-1-infected pregnant women. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston.